Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza

Journal of Infectious Diseases

Volumn 199, Issue 3, 2009, Pages 311-319

  Karlström, Åsa ^a   Boyd, Kelli L ^a   English, B Keith ^b   McCullers, Jonathan A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM; CLINDAMYCIN; CYTOKINE; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIOSTASIS; CELL WALL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; INFLAMMATORY CELL; INFLUENZA; INFLUENZA VIRUS; LUNG; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CLINDAMYCIN; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; INFLAMMATION; INFLUENZA A VIRUS; LUNG; MICE; MICE, INBRED BALB C; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PROTEIN SYNTHESIS INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58849132964     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596051     Document Type: Article

References (48)

1. Miniño AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007; 55:1-119.
2. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
3. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82.
4. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519-26.
5. Hers JFP, Masurel N, Mulder J. Bacteriology and histopathology of the respiratory tract and lungs of fatal Asian influenza. Lancet 1958; 2:1164-5.
6. Lindsay MI Jr, Herrmann EC Jr, Morrow GW Jr, Brown AL Jr. Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA 1970; 214:1825-32.
7. Louria D, Blumenfeld H, Ellis J, Kilbourne ED, Rogers D. Studies on influenza in the pandemic of 1957-58. II. Pulmonary complications of influenza. J Clin Invest 1959; 38:213-65.
8. Martin CM, Kunin CM, Gottlieb LS, Barnes MW, Liu C, Finland M. Asian influenza A in Boston, 1957-1958. I. Observations in thirty-two influenza-associated fatal cases. AMA Arch Intern Med 1959; 103:515-31.
9. Stone WJ, Swift GW. Influenza and influenzal pneumonia at Fort Riley, Kansas. JAMA 1919; 72:487-93.
10. Abrahams A, Hallows N, French H. A further investigation into influenzo-pneumococcal and influenzo-streptococcal septicaemia. Lancet 1919; 1-11.
11. Scadding JG. Lung changes in influenza. Quart J Med 1937; 6:425-65.
12. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. London: Blackwell Science, 1998:222-3.
13. Finland M, Barnes MW, Samper BA. Influenza virus isolations and serological studies made in Boston during the winter of 1943-1944. J Clin Invest 1945; 24:192-208.
14. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341-50.
15. Peltola VT, Boyd KL, McAuley JL, Rehg JE, McCullers JA. Bacterial sinusitis and otitis media following influenza virus infection in ferrets. Infect Immun 2006; 74:2562-7.
16. Smith MW, Schmidt JE, Rehg JE, Orihuela C, McCullers JA. Induction of pro- and anti- inflammatory molecules in a mouse model of pneumococcal pneumonia following influenza. Comp Med 2007; 57:82-9.
17. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-9.
18. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007; 2:240-9.
19. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004; 23(Suppl 1):S87-S97.
20. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249-57.
21. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76.
22. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
23. British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax 2002; 57(Suppl 1):i1-24.
24. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
25. Rahav G, Toledano Y, Engelhard D, et al. Invasive pneumococcal infections: a comparison between adults and children. Medicine (Baltimore) 1997; 76:295-303.
26. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-8.
27. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
28. McCullers JA, Tuomanen EI. Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 2001; 6:D877-89.
29. Orman KL, English BK. Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. J Infect Dis 2000; 182:1561-5.
30. McCullers JA, English BK. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 2008; 3:397-404.
31. Ivetić Tkalcević V, Bosnjak B, Hrvacić B, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 2006; 539:131-8.
32. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324:1525-31.
33. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964-71.
34. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327:864-72.
35. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15:95-110.
36. Schmidt H, Zysk G, Reinert RR, et al. Rifabutin for experimental pneumococcal meningitis. Chemotherapy 1997; 43:264-71.
37. Nau R, Wellmer A, Soto A, et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999; 179:1557-60.
38. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
39. García Vásquez E, Mensa J, Martínez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24:190-5.
40. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-4.
41. Tumpey TM, García-Sastre A, Taubenberger JK, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005; 79:14933-44.
42. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003; 302:1519-22.
43. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
44. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7.
45. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467-71.
46. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7.
47. McCullers JA. Preparing for the next influenza pandemic. Pediatr Infect Dis J 2008; 27:S57-9.
48. Fedson DS. Confronting an imminent pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008; 8:571-6.